非选择性单胺氧化酶抑制剂和内抽胺组合在抑郁症中的心血管影响 - - 准实验性设计与贝叶斯分析
Ludovic C Dormegny-Jeanjean1,2,3, Suzie Lenoir4, Ilia Humbert1,3
1Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of Strasbourg, Strasbourg, France.
Pharmacopsychiatry
|June 2, 2025
概括
与非选择性单胺氧化酶抑制剂 (NS-MAOI) 结合使用的埃斯凯特胺 (ESK) 在治疗耐药抑郁症患者中不会显著增加血压或心率. 这种组合在治疗期间对心血管参数似乎是安全的.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 胺和胺 (ESK) 是对抗性抑郁症的新兴治疗方法.
- 与传统的抗抑郁药不同,ESK可以与非选择性单胺氧化酶抑制剂 (NS-MAOI) 结合使用,而不会引起血清激素综合征.
- 然而,ESK的潜在交感效应可能会增加血压 (BP).
研究的目的:
- 为了研究ESK会议期间心血管参数的变化.
- 评估ESK+NS-MAOI组合是否与高血压有关.
- 评估ESK和NS-MAOI同时使用的安全性.
主要方法:
- 在193次ESK会议 (2018-2022) 中收集了心血管数据 (心率,心压和心压压).
- 测量参数在基线和每30分钟2小时.
- 利用贝叶斯模型分析心血管进化和影响血压升高的因素,比较单独的ESK和ESK+NS-MAOI组.
主要成果:
- 包括NS-MAOI在内的ESK会议显示,SP (+8.68 mmHg),DP (+6.57 mmHg) 和心率 (+3.5 bpm) 的峰值增加,但这些都没有临床意义.
- 在单独ESK和ESK+NS-MAOI组之间没有观察到心血管变化的显著差异.
- 没有确定ESK+NS-MAOI组合是导致血压升高的因素.
结论:
- 即使与NS-MAOI相结合,ESK治疗也显示出极少的临床显著的心血管副作用.
- 结果表明ESK和NS-MAOI之间有限的外周交友协同作用.
- 这项研究提供了证据支持这种组合在抗抑郁症治疗中的心血管安全性.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
831
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
831
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.4K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K